|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSPG4 is a well-established CAR target in cutaneous melanoma.
|
31195686 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
|
31140988 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PES43 lung disseminated tumor cells (DTC) were detected in fresh lung tissues as melanoma positive MCSP-APC<sup>+</sup> cells.
|
31661001 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is found that the chondroitin sulfate proteoglycan-4 (CSPG4)-specific CAR T cells infused in Nod scid gamma mice engrafted with the human melanoma WM115 cell line have superior antitumor activity after photothermal ablation of the tumor.
|
30916367 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, tumor-directed blockade of PD-L1 by PD-L1xCSPG4 may improve efficacy and safety of PD-1/PD-L1 checkpoint blockade for treatment of melanoma and other CSPG4-overexpressing malignancies.
|
31128201 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, we discuss merits and challenges associated with CSPG4-CAR-T cells for the ATT of melanoma, leukemia, glioblastoma, and triple-negative breast cancer.
|
31779130 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We profiled the gene expression of CTC subpopulations immunomagnetic-captured by targeting either the melanoma-associated marker, MCSP, or the melanoma-initiating marker, ABCB5.
|
30769764 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
|
29565434 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of the chondroitin sulfate proteoglycan 4 (CSPG4) has been associated with the pathology of multiple types of such as melanoma, breast cancer, squamous cell carcinoma, mesothelioma, neuroblastoma, adult and pediatric sarcomas, and some hematological cancers.
|
29375561 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously reported on a mimotope-based vaccine against CSPG4 in a human melanoma xenograft model that resulted in reduction of tumor growth.
|
25997619 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma.
|
24258997 |
2014 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study provides a foundation for future investigations designed to improve BRAF inhibitor effectiveness in vitro and in vivo for treating melanoma(BRAF(V600E)/CSPG4+) cells in combination with a CSPG4-specific mAb.
|
21717063 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.
|
21829586 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Viable CSPG4(+) melanoma cells were used in a screen of a human scFv phage display library that included CDR3 engineered to optimize antibody binding sites.
|
22021902 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In case of the MCSP antigen, this provides the basis for selection of a maximally potent BiTE antibody candidate for development of a novel melanoma therapy.
|
20309546 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MCSP is a well-established target for melanoma immunotherapy and has recently been shown to provide important tumorigenic signals to melanoma cells.
|
21092273 |
2010 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MCSP expression in melanoma cells enhances integrin function and constitutive activation of Erk1,2.
|
19738072 |
2009 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes.
|
18519770 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using intravital microscopy, histological analysis, alpha-smooth muscle actin and chondroitin sulfate proteoglycan 4 staining, microsensor NO measurements, and an NO synthase (NOS) inhibitor, we found that NO mediates mural cell coverage as well as vessel branching and longitudinal extension but not the circumferential growth of blood vessels in B16 murine melanomas.
|
15951843 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma chondroitin sulfate proteoglycan (MCSP) is an early cell surface melanoma progression marker implicated in stimulating tumor cell proliferation, migration, and invasion.
|
15210734 |
2004 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
These results indicate that MCSP may facilitate primary melanoma progression by enhancing the activation of key signaling pathways important for tumor invasion and growth.
|
15210734 |
2004 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The availability of cDNAs encoding MCSP should facilitate studies designed to establish correlations between structure and function of this molecule and help to establish its role in the progression of human malignant melanoma.
|
8790396 |
1996 |